Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy
Study Details
Study Description
Brief Summary
Osteoporosis and osteoporotic fractures, especially hip fractures, have a significant impact on public healthcare. Despite the fact that the patients that have suffered an osteoporotic fracture have 86% increased risk of sustaining a second osteoporotic fracture, the efforts to prevent these fractures remain inadequate. The in-hospital initiation of antiosteoporotic treatment in patients that have been admitted due to hip fracture has shown to improve treatment rates and contribute to second fracture prevention. For this purpose the Arbeitsgemeinschaft für Osteosynthesefragen (AO) Foundation has introduced an algorithm that can be used by Orthopedic surgeons for the prevention of second fracture in patients that have already suffered an osteoporotic fracture. The purpose of this thesis is to study the efficacy of this algorithm in preventing the second fracture in the greek population. The study will include patients that have been admitted in the Orthopedics department of the University Hospital of Heraklion due to hip fracture. Bone density measurement will be performed using the DXA method and antiosteoporotic treatment will be administered according to the algorithm. These patients will be included in the hip registry of the Orthopedics department and the follow-up will last for 2 years .The primary aims of the study are: a)evaluation of the adherence to the antiosteoporotic medication b)the efficacy of the adherence to the aforementioned clinical algorithm in the secondary fracture prevention in the greek population.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Patients adherent to the anti-osteoporotic medication
|
Drug: Anti-osteoporotic medication( alendronate or denosumab)
Initiation of anti-osteoporotic medication (alendronate or denosumab)
|
Patients non-adherent to the anti-osteoporotic medication
|
Drug: Anti-osteoporotic medication( alendronate or denosumab)
Initiation of anti-osteoporotic medication (alendronate or denosumab)
|
Outcome Measures
Primary Outcome Measures
- Adherence to the prescribed anti-osteoporotic medication [1 year]
- Secondary fracture incidence [1 year]
Secondary Outcome Measures
- Morbidity and mortality of operatively treated hip fractures in our department [1 year]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with hip fractures after low-energy falls(fragility fractures)
Exclusion Criteria:
-Patients with hip fractures after high energy falls
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University Hospital of Heraklion | Heraklion | Crete | Greece | 71500 |
Sponsors and Collaborators
- University General Hospital of Heraklion
Investigators
- Principal Investigator: Ioannis Daskalakis, Orthopaedic Surgery Resident, University Hospital of Heraklion
- Study Director: Theodoros Tosounidis, Assistant Professor, University Hospital of Heraklion
- Study Chair: Apostolos Karantanas, Professor, University Hospital of Heraklion
- Study Chair: Georgios Kontakis, Professor, University Hospital of Heraklion
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 3224